PDCD1 and cancer: Because only few patients with CHB have been treated with checkpoint inhibitors in Phase 1/2 clinical trials, we compared HBV-specific T cell functional restoration to an assay able to predict overall survival in cancer patients, the interferon response capacity (IRC).36 We demonstrate differential responses to PD-1 blockade by cytokine, clinical phase, and HBV antigen specificity.